Cefoselis
Names | |
---|---|
IUPAC name (6R,7R)-3-[[3-amino-2-(2-hydroxyethyl)pyrazol-1-ium-1-yl]methyl]-7-[[(2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-methoxyiminoacetyl]amino]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate | |
Other names Wincef | |
Identifiers | |
3D model (JSmol) | |
ChEMBL | |
ChemSpider | |
PubChem CID | |
UNII | |
CompTox Dashboard (EPA) | |
| |
| |
Properties | |
C19H22N8O6S2 | |
Molar mass | 522.55 g·mol−1 |
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa). |
Cefoselis is a fourth generation cephalosporin. It is used extensively in Japan and China in the clinical treatment of various gram positive and gram negative infections. A 2014 study illustrated that Cefoselis is effective at treating respiratory and urinary tract infections.[1]
References
[edit]- ^ "Multicenter, double-blind, randomized clinical trial of parenterally administered Cefoselis versus Cefepime for the treatment of acute bacterial infections". European Review. 2014-07-10. Retrieved 2022-08-03.